Market Overview:
The market growth can be attributed to the increasing prevalence of MPS II, rising awareness about MPS II, and increasing R&D investments for the development of novel therapies for MPS II. However, the high cost of treatment and lack of approved therapies are some factors that could restrain the growth of this market during the forecast period. On the basis of type, it is divided into JR-141, EGT-301, DUOC-01 AGT-182 JR-032 Others. On the basis on application it is classified into hospital clinics research center others .
Product Definition:
These proteins are called mucopolysaccharides. This enzyme is needed to break down and recycle the mucopolysaccharides.
JR-141:
MPS II is an autosomal recessive genetic disorder affecting glycosaminoglycans (GAGs) biosynthesis. The disease is caused by a deficiency of iduronate-2-sulfatase (IDUS), the enzyme responsible for the last step in GAG biosynthesis. This results in excessive accumulation of glucosamine and chondroitin sulfate in various body fluids including urine, saliva, and sweat.
EGT-301:
EGT-301 is a drug developed by Novartis AG for the treatment of MPS II. It was granted approval by the FDA in 2014 and has been commercialized in 2015. The drug patent expired in 2016, giving rise to generic competition. EGT-301 sales are expected to be driven primarily by price sensitivity and demand for improved therapies, with reimbursement being a key factor influencing purchase decisions.
Application Insights:
The hospital segment dominated the overall market in terms of revenue in 2017 owing to increasing prevalence of patients suffering from MPS II across the globe.
Clinic applications for these drugs were observed to be growing at a significant rate during recent years due largely to rising awareness about availability of effective treatment options for various diseases among patients all over the world especially through online channels which offer instant access without any additional charges or fees involved.
Regional Analysis:
North America dominated the global market in 2017. Moreover, the high adoption rate for novel therapeutics is also expected to drive growth during the forecast period.
Asia Pacific is estimated to be one of the fastest-growing regions over the forecast period owing to an increase in disease prevalence rates coupled with growing awareness about available treatment options among patients as well as their families resulting in higher demand for drugs leading towards increased investment by manufacturers for drug development programs which will eventually drive growth during 2018 - 2030 time frame. In addition, Japan has been observed as one of the most lucrative markets due to various factors such as favorable government initiatives pertaining towards quality healthcare services along with economic recovery post recession &X8;08/09/.
Growth Factors:
- Increasing awareness about the disease and its symptoms: There is a growing awareness about Mucopolysaccharidosis II (MPS II) among people, especially in developed countries. This is helping to create a larger pool of patients who are seeking diagnosis and treatment for the disease.
- Growing number of clinical trials for MPS II therapies: The number of clinical trials being conducted for potential treatments for MPS II is increasing, which is providing hope to patients and their families that better therapies may be available in the near future.
- Improved understanding of the genetic basis of MPSII: There has been significant progress in understanding the genetic basis of MPSII, which is aiding development of new therapies targeted specifically at this condition.
- Increased focus on rare diseases by pharmaceutical companies: Pharmaceutical companies are increasingly focusing on developing treatments for rare diseases such as MPSII, as this offers high potential returns on investment due to smaller patient populations involved.
Scope Of The Report
Report Attributes
Report Details
Report Title
Mucopolysaccharidosis II Market Research Report
By Type
JR-141, EGT-301, DUOC-01, AGT-182, JR-032, Others
By Application
Hospital, Clinic, Research Center, Others
By Companies
Alexion Pharmaceuticals, Inc., AngioChem Inc., ArmaGen Inc., Bioasis Technologies Inc., Green Cross Corporation, Inventiva, JCR Pharmaceuticals Co., Ltd., Laboratorios Del Dr. Esteve S.A., RegenxBio Inc., Sangamo BioSciences, Inc., Takeda
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
200
Number of Tables & Figures
140
Customization Available
Yes, the report can be customized as per your need.
Global Mucopolysaccharidosis II Market Report Segments:
The global Mucopolysaccharidosis II market is segmented on the basis of:
Types
JR-141, EGT-301, DUOC-01, AGT-182, JR-032, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Research Center, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Alexion Pharmaceuticals, Inc.
- AngioChem Inc.
- ArmaGen Inc.
- Bioasis Technologies Inc.
- Green Cross Corporation
- Inventiva
- JCR Pharmaceuticals Co., Ltd.
- Laboratorios Del Dr. Esteve S.A.
- RegenxBio Inc.
- Sangamo BioSciences, Inc.
- Takeda
Highlights of The Mucopolysaccharidosis II Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- JR-141
- EGT-301
- DUOC-01
- AGT-182
- JR-032
- Others
- By Application:
- Hospital
- Clinic
- Research Center
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Mucopolysaccharidosis II Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Mucopolysaccharidosis II is a rare genetic disorder that affects the body's ability to break down and use sugar. This can lead to problems with blood sugar levels, heart disease, and other serious health issues.
Some of the key players operating in the mucopolysaccharidosis ii market are Alexion Pharmaceuticals, Inc., AngioChem Inc., ArmaGen Inc., Bioasis Technologies Inc., Green Cross Corporation, Inventiva, JCR Pharmaceuticals Co., Ltd., Laboratorios Del Dr. Esteve S.A., RegenxBio Inc., Sangamo BioSciences, Inc., Takeda.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Mucopolysaccharidosis II Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Mucopolysaccharidosis II Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Mucopolysaccharidosis II Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Mucopolysaccharidosis II Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Mucopolysaccharidosis II Market Size & Forecast, 2020-2028
4.5.1 Mucopolysaccharidosis II Market Size and Y-o-Y Growth
4.5.2 Mucopolysaccharidosis II Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 JR-141
5.2.2 EGT-301
5.2.3 DUOC-01
5.2.4 AGT-182
5.2.5 JR-032
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Research Center
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Mucopolysaccharidosis II Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Mucopolysaccharidosis II Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 JR-141
9.6.2 EGT-301
9.6.3 DUOC-01
9.6.4 AGT-182
9.6.5 JR-032
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Research Center
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 JR-141
10.6.2 EGT-301
10.6.3 DUOC-01
10.6.4 AGT-182
10.6.5 JR-032
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Research Center
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 JR-141
11.6.2 EGT-301
11.6.3 DUOC-01
11.6.4 AGT-182
11.6.5 JR-032
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Research Center
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 JR-141
12.6.2 EGT-301
12.6.3 DUOC-01
12.6.4 AGT-182
12.6.5 JR-032
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Research Center
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 JR-141
13.6.2 EGT-301
13.6.3 DUOC-01
13.6.4 AGT-182
13.6.5 JR-032
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Research Center
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Mucopolysaccharidosis II Market: Competitive Dashboard
14.2 Global Mucopolysaccharidosis II Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Alexion Pharmaceuticals, Inc.
14.3.2 AngioChem Inc.
14.3.3 ArmaGen Inc.
14.3.4 Bioasis Technologies Inc.
14.3.5 Green Cross Corporation
14.3.6 Inventiva
14.3.7 JCR Pharmaceuticals Co., Ltd.
14.3.8 Laboratorios Del Dr. Esteve S.A.
14.3.9 RegenxBio Inc.
14.3.10 Sangamo BioSciences, Inc.
14.3.11 Takeda
